CA3113682A1 - Methods of preparing and analyzing nucleic acid libraries - Google Patents
Methods of preparing and analyzing nucleic acid libraries Download PDFInfo
- Publication number
- CA3113682A1 CA3113682A1 CA3113682A CA3113682A CA3113682A1 CA 3113682 A1 CA3113682 A1 CA 3113682A1 CA 3113682 A CA3113682 A CA 3113682A CA 3113682 A CA3113682 A CA 3113682A CA 3113682 A1 CA3113682 A1 CA 3113682A1
- Authority
- CA
- Canada
- Prior art keywords
- target
- primers
- amplification
- wga
- cases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 97
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 64
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 62
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 62
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 203
- 230000003321 amplification Effects 0.000 claims abstract description 202
- 108091093088 Amplicon Proteins 0.000 claims abstract description 62
- 238000012163 sequencing technique Methods 0.000 claims abstract description 47
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 42
- 239000002773 nucleotide Substances 0.000 claims abstract description 31
- 230000035772 mutation Effects 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 238000013412 genome amplification Methods 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 63
- 108020004414 DNA Proteins 0.000 claims description 42
- 238000003556 assay Methods 0.000 claims description 26
- 238000001574 biopsy Methods 0.000 claims description 20
- 210000002257 embryonic structure Anatomy 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 230000000295 complement effect Effects 0.000 claims description 15
- 210000001161 mammalian embryo Anatomy 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 9
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 230000003252 repetitive effect Effects 0.000 claims description 9
- 108091092878 Microsatellite Proteins 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 8
- 230000008018 melting Effects 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 230000008774 maternal effect Effects 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 230000005945 translocation Effects 0.000 claims description 6
- 206010008805 Chromosomal abnormalities Diseases 0.000 claims description 5
- 208000031404 Chromosome Aberrations Diseases 0.000 claims description 5
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 4
- 230000002357 endometrial effect Effects 0.000 claims description 4
- 210000001808 exosome Anatomy 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 210000002220 organoid Anatomy 0.000 claims description 4
- 108010077544 Chromatin Proteins 0.000 claims description 3
- 210000004381 amniotic fluid Anatomy 0.000 claims description 3
- 210000004952 blastocoel Anatomy 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 3
- 239000013592 cell lysate Substances 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000003467 cheek Anatomy 0.000 claims description 3
- 210000003763 chloroplast Anatomy 0.000 claims description 3
- 210000003483 chromatin Anatomy 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 210000001771 cumulus cell Anatomy 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- 210000004700 fetal blood Anatomy 0.000 claims description 3
- 230000001605 fetal effect Effects 0.000 claims description 3
- 210000002503 granulosa cell Anatomy 0.000 claims description 3
- 210000003780 hair follicle Anatomy 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 210000003470 mitochondria Anatomy 0.000 claims description 3
- 210000002445 nipple Anatomy 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 238000007790 scraping Methods 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000004243 sweat Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 238000003752 polymerase chain reaction Methods 0.000 claims description 2
- 210000002993 trophoblast Anatomy 0.000 claims description 2
- 238000012216 screening Methods 0.000 abstract description 12
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract description 7
- 230000002068 genetic effect Effects 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 abstract description 6
- 238000002513 implantation Methods 0.000 abstract description 4
- 238000003205 genotyping method Methods 0.000 abstract description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 49
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 49
- 101150029409 CFTR gene Proteins 0.000 description 29
- 239000003153 chemical reaction reagent Substances 0.000 description 19
- 238000001514 detection method Methods 0.000 description 17
- 238000007857 nested PCR Methods 0.000 description 16
- 108700028369 Alleles Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 11
- 210000000349 chromosome Anatomy 0.000 description 11
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 8
- 239000010931 gold Substances 0.000 description 8
- 229910052737 gold Inorganic materials 0.000 description 8
- 239000003607 modifier Substances 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108091008109 Pseudogenes Proteins 0.000 description 6
- 102000057361 Pseudogenes Human genes 0.000 description 6
- 208000036878 aneuploidy Diseases 0.000 description 6
- 231100001075 aneuploidy Toxicity 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 102100031780 Endonuclease Human genes 0.000 description 5
- 208000026350 Inborn Genetic disease Diseases 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000016361 genetic disease Diseases 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000000654 solvent vapour annealing Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000007481 next generation sequencing Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102200128169 rs77932196 Human genes 0.000 description 4
- 108091023043 Alu Element Proteins 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108091092584 GDNA Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241001156002 Anthonomus pomorum Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100172886 Caenorhabditis elegans sec-6 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 2
- 108091036407 Polyadenylation Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 208000031655 Uniparental Disomy Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 201000003426 X-linked dystonia-parkinsonism Diseases 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- -1 etc. by column-based Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 2
- 208000012978 nondisjunction Diseases 0.000 description 2
- 230000008775 paternal effect Effects 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- HRSYWPMGIIAQIW-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1,4-benzodioxine-7-carbaldehyde Chemical compound O1CCOC2=C1C=C(C=O)C=C2Br HRSYWPMGIIAQIW-UHFFFAOYSA-N 0.000 description 1
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 1
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 108700004546 Congenital disorder of glycosylation type 1A Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010066946 Craniofacial dysostosis Diseases 0.000 description 1
- 201000006526 Crouzon syndrome Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108010001132 DNA Polymerase beta Proteins 0.000 description 1
- 102000001996 DNA Polymerase beta Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 208000011345 Duchenne and Becker muscular dystrophy Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014490 Elliptocytosis hereditary Diseases 0.000 description 1
- 102100034239 Emerin Human genes 0.000 description 1
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 208000001730 Familial dysautonomia Diseases 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000021097 Glutaryl-CoA dehydrogenase deficiency Diseases 0.000 description 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000001825 Hereditary elliptocytosis Diseases 0.000 description 1
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 206010050469 Holt-Oram syndrome Diseases 0.000 description 1
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 1
- 101100400478 Homo sapiens MAST2 gene Proteins 0.000 description 1
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 description 1
- 241000713887 Human endogenous retrovirus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000007031 Incontinentia pigmenti Diseases 0.000 description 1
- 102100034389 Low density lipoprotein receptor adapter protein 1 Human genes 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
- 208000012583 Menkes disease Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 208000003452 Multiple Hereditary Exostoses Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 208000016899 PMM2-CDG Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 201000001638 Riley-Day syndrome Diseases 0.000 description 1
- 101100076570 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MER1 gene Proteins 0.000 description 1
- 101100033336 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) REC107 gene Proteins 0.000 description 1
- 108020004487 Satellite DNA Proteins 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 201000007410 Smith-Lemli-Opitz syndrome Diseases 0.000 description 1
- 108090001068 Spastin Proteins 0.000 description 1
- 102000004880 Spastin Human genes 0.000 description 1
- 208000014042 Spondylometaphyseal dysplasia Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000205101 Sulfolobus Species 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 206010043390 Thalassaemia alpha Diseases 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 201000006288 alpha thalassemia Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 208000006112 autosomal recessive hypercholesterolemia Diseases 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 208000024668 brittle bone disease Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 1
- 208000032655 familial 4 hypercholesterolemia Diseases 0.000 description 1
- 238000004374 forensic analysis Methods 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- 208000007938 hereditary pyropoikilocytosis Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000033066 hyperinsulinemic hypoglycemia Diseases 0.000 description 1
- 230000000396 hypokalemic effect Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 201000002273 mucopolysaccharidosis II Diseases 0.000 description 1
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000002761 neurofibromatosis 2 Diseases 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000029308 periodic paralysis Diseases 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 210000004508 polar body Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 102200128219 rs75527207 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 230000020509 sex determination Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- KJFVITRRNTVAPC-UHFFFAOYSA-L tetramethylazanium;sulfate Chemical compound C[N+](C)(C)C.C[N+](C)(C)C.[O-]S([O-])(=O)=O KJFVITRRNTVAPC-UHFFFAOYSA-L 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000018412 transposition, RNA-mediated Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000000143 trophectoderm cell Anatomy 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806698P | 2019-02-15 | 2019-02-15 | |
| US62/806,698 | 2019-02-15 | ||
| PCT/US2020/018360 WO2020168239A1 (en) | 2019-02-15 | 2020-02-14 | Methods of preparing and analyzing nucleic acid libraries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3113682A1 true CA3113682A1 (en) | 2020-08-20 |
Family
ID=72044119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3113682A Pending CA3113682A1 (en) | 2019-02-15 | 2020-02-14 | Methods of preparing and analyzing nucleic acid libraries |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210381035A1 (enExample) |
| EP (1) | EP3924489A4 (enExample) |
| JP (2) | JP7518084B2 (enExample) |
| CN (1) | CN113166757A (enExample) |
| CA (1) | CA3113682A1 (enExample) |
| WO (1) | WO2020168239A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114807360B (zh) * | 2022-06-27 | 2022-09-02 | 北京贝瑞和康生物技术有限公司 | 检测脆性x综合征突变的方法和试剂盒 |
| CN116286714A (zh) * | 2022-12-08 | 2023-06-23 | 广州市金圻睿生物科技有限责任公司 | 一种融合型Taq DNA聚合酶及其制备方法和应用 |
| CN116814766A (zh) * | 2023-05-06 | 2023-09-29 | 中国人民解放军总医院第一医学中心 | 基于单细胞全基因组扩增的耳聋无创产前诊断试剂盒 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8206913B1 (en) * | 2003-03-07 | 2012-06-26 | Rubicon Genomics, Inc. | Amplification and analysis of whole genome and whole transcriptome libraries generated by a DNA polymerization process |
| DK1604040T3 (da) | 2003-03-07 | 2011-01-24 | Rubicon Genomics Inc | Amplifikation og analyse af hele genom- og hele transkriptom-biblioteket genereret ved en DNA-polymerisationsproces |
| WO2005118773A2 (en) * | 2004-05-28 | 2005-12-15 | Wafergen, Inc. | Apparatus and methods for multiplex analyses |
| US20110033862A1 (en) * | 2008-02-19 | 2011-02-10 | Gene Security Network, Inc. | Methods for cell genotyping |
| US20090291475A1 (en) * | 2008-04-23 | 2009-11-26 | Kai Qin Lao | Sequence amplification with linear primers |
| SG183029A1 (en) * | 2009-01-13 | 2012-08-30 | Fluidigm Corp | Single-cell nucleic acid analysis |
| US10004561B2 (en) | 2012-10-15 | 2018-06-26 | Life Genetics Lab, Llc | Method for genetic detection using interspersed genetic elements: a multiplexed DNA analysis system |
| US9909186B2 (en) * | 2012-12-14 | 2018-03-06 | Chronix Biomedical | Personalized biomarkers for cancer |
| US10262755B2 (en) * | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
| US10208339B2 (en) * | 2015-02-19 | 2019-02-19 | Takara Bio Usa, Inc. | Systems and methods for whole genome amplification |
| US20190345538A1 (en) * | 2016-03-31 | 2019-11-14 | PerkinElmer Health Sciences (Australia) Pty Ltd | Amplification of target sequences |
| US10995370B2 (en) * | 2016-09-22 | 2021-05-04 | Invitae Corporation | Methods, systems and processes of identifying genetic variations |
| AU2019359771B2 (en) * | 2018-10-17 | 2025-09-18 | Revvity Holdings, Inc. | Barcoding of nucleic acids |
-
2020
- 2020-02-14 JP JP2021547127A patent/JP7518084B2/ja active Active
- 2020-02-14 CA CA3113682A patent/CA3113682A1/en active Pending
- 2020-02-14 EP EP20755655.6A patent/EP3924489A4/en active Pending
- 2020-02-14 CN CN202080006350.2A patent/CN113166757A/zh active Pending
- 2020-02-14 US US17/276,771 patent/US20210381035A1/en active Pending
- 2020-02-14 WO PCT/US2020/018360 patent/WO2020168239A1/en not_active Ceased
-
2024
- 2024-07-04 JP JP2024108454A patent/JP2024147609A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022520794A (ja) | 2022-04-01 |
| EP3924489A4 (en) | 2022-11-23 |
| WO2020168239A1 (en) | 2020-08-20 |
| EP3924489A1 (en) | 2021-12-22 |
| JP7518084B2 (ja) | 2024-07-17 |
| JP2024147609A (ja) | 2024-10-16 |
| CN113166757A (zh) | 2021-07-23 |
| US20210381035A1 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mamanova et al. | Target-enrichment strategies for next-generation sequencing | |
| EP3108009B1 (en) | Methods and compositions for dna profiling | |
| Pask et al. | Investigating the utility of combining Φ29 whole genome amplification and highly multiplexed single nucleotide polymorphism BeadArray™ genotyping | |
| EP2248914A1 (en) | The use of class IIB restriction endonucleases in 2nd generation sequencing applications | |
| JP2024147609A (ja) | 核酸ライブラリを調製及び分析する方法 | |
| Niedzicka et al. | Molecular Inversion Probes for targeted resequencing in non-model organisms | |
| EP3702457A1 (en) | Reagents, kits and methods for molecular barcoding | |
| JP2014507164A (ja) | ハプロタイプ決定のための方法およびシステム | |
| JP7653924B2 (ja) | 近接ライゲーションのための方法および組成物 | |
| Gorden et al. | Capture enrichment and massively parallel sequencing for human identification | |
| Patel et al. | Advances in plant genotyping: where the future will take us | |
| Nicod et al. | SNPs by AFLP (SBA): a rapid SNP isolation strategy for non‐model organisms | |
| England et al. | A review of the method and validation of the MiSeq FGx™ Forensic Genomics Solution | |
| JP6908615B2 (ja) | ヌクレアーゼ保護を使用する直接標的シーケンシングの方法 | |
| US20180305683A1 (en) | Multiplexed tagmentation | |
| US20230416730A1 (en) | Methods and compositions for addressing inefficiencies in amplification reactions | |
| Singh et al. | Sequence-based markers | |
| AU2019359771A1 (en) | Barcoding of nucleic acids | |
| CN114507707B (zh) | 一种富集目标区域再酶切构建单倍型的方法 | |
| US20230313281A1 (en) | Methods and Compositions For Preparing Nucleic Acids For Genetic Analysis | |
| Lefferts et al. | Essential concepts and techniques in molecular biology | |
| Sathyanarayana et al. | Applications of Long-Read Sequencing Technology in Clinical Genomics | |
| US20210180125A1 (en) | Method for the detection and quantification of genetic alterations | |
| WO2024054517A1 (en) | Methods and compositions for analyzing nucleic acid | |
| WO2024015869A2 (en) | Systems and methods for variant detection in cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |